

## Index

- abdominal ectopic pregnancy, 277  
 features, 279  
 pathogenesis for, 278
- aberrant tissue bands. *See* amnionic band syndrome
- ABMC. *See* androgenetic biparental mosaicism
- abnormal contour, in placenta, 161–63  
 clinical context, 162  
 diagnosis for, 163  
 features, 162–63  
 pathogenesis for, 162  
 prognosis for, 163
- abnormal distal villous vascular pattern. *See* distal villous vascular pattern
- abnormal placental location. *See also* ectopic pregnancies  
 defined, 275  
 placenta previa, 275–76  
 clinical context, 275  
 features, 275–76  
 pathogenesis for, 275  
 prognosis for, 276  
 risk factors for, 275  
 types of, 275
- abruptio placentae  
 acute, 70–72  
 clinical context, 70  
 features, 71, 72  
 pathogenesis for, 70–71  
 prognosis for, 71–72
- subacute, 75  
 clinical context, 75  
 features, 74, 75  
 pathogenesis, 75  
 prognosis for, 75
- ABS. *See* amnionic band syndrome
- acardius acephalus, 252
- accelerated villous maturation (AVM), 62–65  
 autoimmune disease and, 62  
 clinical context for, 62  
 diagnosis of, 64  
 features, 62–64  
 fetal growth restriction (FGR) and, 62  
 fibrinoid necrosis and, 63–64  
 IUFD and, 64  
 pathogenesis for, 62  
 increased fibrin production, 62  
 placental mosaicism and, 62  
 preeclampsia and, 62  
 pregestational diabetes and, 62  
 prognosis for, 64
- accessory lobe, 161–63
- active maternal disease processes, 12–14  
 clinical context, 12–13  
 features of, 13–14  
 management options, 13  
 noninfectious, 12–13  
 pathogenesis for, 13  
 prognosis for, 14
- acute abruption placentae. *See* abruptio placentae
- acute atherosclerosis. *See* atherosclerosis
- acute myelogenous leukemia (AML), 225
- acute purulent myometritis. *See* purulent myometritis
- acute villitis. *See* villitis
- acute villous edema. *See* villous edema
- ADAM complex. *See* adhesion mutilation complex
- adherent membranes. *See* retained products of conception
- adhesion mutilation (ADAM) complex, 214–16. *See also* amnionic band syndrome
- adrenocortical heterotopia, 231–32  
 ancillary diagnostic testing for, 232  
 clinical context, 231  
 features, 231, 232  
 pathogenesis for, 231  
 prognosis for, 232
- allantoic duct cyst, 173–76
- AML. *See* acute myelogenous leukemia
- amnion chorion dehiscence, 216–17
- amnion nodosum, 217–19  
 ancillary diagnostic testing for, 218  
 clinical context, 217  
 features, 218  
 pathogenesis for, 217–18  
 prognosis for, 218–19  
 squamous metaplasia, 218, 219
- amnion rupture, late, 216–17  
 clinical context, 216  
 features, 216–17  
 pathogenesis, 216
- amnionic adhesion malformation sequence. *See* amnionic band syndrome
- amnionic band syndrome (ABS), 214–16  
 ancillary diagnostic testing for, 215, 216  
 clinical context, 214  
 features, 215–16  
 pathogenesis for, 214–15  
 prognosis for, 216
- amniotic fluid infection, 318
- amniotic fluid leakage, 216–17. *See also* amnion rupture
- androgenetic biparental mosaicism (ABMC), with/without hydatidiform mole, 87–90. *See also* placental mesenchymal dysplasia
- aneurysms. *See* early pregnancy loss
- aneuploidies, 16  
 parentally inherited, 327
- aneusomy, 23
- angiomyxoma, 174, 175
- anti-phospholipid antibodies, 70, 327–28
- ART. *See* assisted reproductive technology
- arteriopathy. *See* decidual arteriopathy; hypertrophic arteriopathy
- arteriovenous malformations, 173–76
- Asherman syndrome, 284
- aspirin, for active maternal disease processes, 12–13
- assisted reproductive technology (ART), 242, 263, 266, 268–69
- atherosclerosis, acute, 53–55. *See also* decidual arteriopathy
- atretic umbilical artery, 171–73
- atypical implantation site. *See* exaggerated implantation site
- atypical intraplacental hemorrhages. *See* intraplacental hemorrhages
- atypical placental site nodule. *See* placental site nodule
- atypical twinning, 242
- atypical villus morphology, 17–19, 85–87. *See also* dysmorphic villi; early pregnancy loss

- autoimmune disease, 62
- avascular villi, 93, 100. *See also* early pregnancy loss; fetal vascular malperfusion
- AVM. *See* accelerated villous maturation
- B cell leukemia, 224
- Bartter syndrome, 238–39  
ancillary diagnostic testing for, 239  
clinical context, 238  
features, 239  
pathogenesis for, 238–39  
prognosis for, 239
- basal chronic VUE, 142
- basal intervillous thrombus, 192
- basal plate arteries. *See* persistent muscularization of basal plate arteries
- basal plate microcysts, 51–53. *See also* excessive immature extravillous trophoblast
- basal plate myofibers. *See* myometrial fibers adherent to the basal plate
- basal plate plaque, 195–97  
clinical context, 196  
differential diagnosis for, 196  
features, 196  
pathogenesis for, 196  
prognosis for, 197
- Beckwith-Wiedemann syndrome, 80, 83, 85
- bilobate placenta, 163–64  
clinical context, 163  
features, 164  
pathogenesis for, 163–64
- bilobed placenta, 161–63
- biparental complete hydatidiform mole, 25
- blighted ovum, 16–17. *See also* early pregnancy loss
- BPMYO. *See* myometrial fibers adherent to the basal plate
- Breus' mole, 73, 188–90. *See also* massive subchorial thrombohematoma
- Candida albicans*, 125, 127
- CAOS. *See* chronic abruption oligohydramnios syndrome
- capillary vessels  
abnormalities of fetal vascular malperfusion (FVM)  
gross features of, by location, 96  
microscopic features, by location, 98–101  
villous edema and, 104
- capillary-vascular lesions  
chorangiomas, 80–82  
clinical context, 80  
diagnosis for, 81–82  
features, 80–81  
pathogenesis for, 80  
prognosis for, 82  
recurrent pregnancy loss, 329
- chorangiomas. *See also* multifocal chorangiomas  
diffuse, 82–83  
features, 80–81  
pathogenesis for, 80  
prognosis for, 82
- multifocal chorangiomas, 82–83  
Beckwith-Wiedemann syndrome, 83  
clinical context, 82  
features, 82–83  
pathogenesis for, 82  
prognosis for, 83
- villous chorangiosis, 79–80  
Beckwith-Wiedemann syndrome and, 80  
clinical context, 79  
diagnosis of, 80  
features, 80  
pathogenesis for, 79–80  
prognosis for, 80
- central nervous system (CNS) injury, 322–23  
chronic villitis and, 323  
delayed villous maturation and, 323–24  
diffuse villous edema and, 324  
etiology of, 322  
fetal vascular malperfusion and, 323  
histiologic chorioamnionitis, 323  
inflammatory processes, 322–23  
lesions, 323–24  
maternal vascular malperfusion and, 323  
meconium effects and, 324  
retroplacental hemorrhages and, 324
- centrally hemorrhagic villous infarcts, 66–67, 192–95. *See also* rounded intraplacental hematoma
- cerebral palsy, 112
- cervical ectopic pregnancy, 277  
features, 278–79, 280  
pathogenesis for, 278
- cervical insufficiency. *See* spontaneous preterm birth
- cesarean scar pregnancy (CSP), 291–92  
clinical context, 291  
features, 291–92  
pathogenesis for, 291  
prognosis for, 292
- CHI. *See* histiocytic intervillitis
- chimerism mechanism, 28
- CHM. *See* complete hydatidiform mole
- chorangiomas, 80–82  
clinical context, 80  
diagnosis for, 81–82  
features, 80–81  
pathogenesis for, 80  
prognosis for, 82  
recurrent pregnancy loss, 329
- chorangiomas. *See also* multifocal chorangiomas  
diffuse, 82–83  
features, 80–81  
pathogenesis for, 80  
prognosis for, 82  
recurrent pregnancy loss, 329
- chorioamnionitis, acute, 70, 71, 123–29  
*Candida albicans* and, 125, 127  
chronic, 139, 142  
clinical context, 123–24  
diagnosis for, 126–27  
features, 124–28  
fetal response in, 128  
funisitis, 124, 125  
giant cell villitis and, 123  
maternal response in, 127  
necrotizing, 125  
pathogenesis for, 124  
prognosis for, 127–28  
obstetric complications, 128  
perinatal morbidities, 127–28  
silent, 124  
stillbirth and, 121  
subacute, 129  
syphilis and, 123  
toxoplasmosis and, 122  
umbilical cord and, 121  
surface abscesses, 125
- choriocarcinoma, 32–33  
ancillary diagnosis of, 33  
clinical context for, 32  
differential diagnosis of, 33  
features of, 32–33  
pathogenesis for, 32  
prognosis for, 33  
in situ or intraplacental, 33–34  
clinical context for, 33  
differential diagnosis of, 34  
features for, 33–34  
pathogenesis for, 33  
prognosis for, 34
- chorionic cysts, 51–53. *See also* excessive immature extravillous trophoblast  
excessive immature extravillous trophoblast and, 51, 52–53
- chorionic villi, 4, 5  
abnormalities in, 5  
first trimester, 4–5  
GCM1, 5  
in partial hydatidiform mole, 22  
syncytiotrophoblast, 4–5  
tertiary, 5
- chorionic villous hemorrhage, 107–8. *See also* intravillous hemorrhage
- chorionicity. *See* dichorionic twins; monochorionic diamniotic twins
- chronic abruption oligohydramnios syndrome (CAOS), 73, 75–76
- chronic chorioamnionitis, 139, 142, 145–47  
clinical context, 145
- chorioamnionic rupture sequence. *See* amnionic band syndrome

## Index

- chronic chorioamnionitis (cont.)  
 diagnosis of, 146  
 features, 145–46  
 pathogenesis for, 145  
 prognosis for, 146–47  
 staging of, 146, 147
- chronic deciduitis. *See* deciduitis
- chronic events, for fetal death, 319–20
- chronic histiocytic intervillitis,  
 319
- giant chorangioma, 320
- maternal floor infarction, 319
- maternal vascular malperfusion, 319
- mesenchymal dysplasia, 320
- multifocal chorangiomatosis, 320
- non-infectious chronic villitis, 319
- placental hydrops, 319
- VUE, 319
- chronic histiocytic intervillitis. *See*  
 histiocytic intervillitis
- chronic perivasculitis. *See*  
 perivasculitis
- chronic villitis, 14, 118–23. *See also*  
 villitis of unknown etiology
- clinical context, 118
- CMV and, 119, 120
- diagnosis of, 122
- diffuse, 119
- features, 118–22
- HPV, 123
- HSV and, 120
- with intervillitis, 120
- pathogenesis, 118
- prognosis for, 122–23
- recurrent pregnancy loss, 328
- T. gondii* and, 120–21
- T. pallidum* and, 121–22
- circumvallation, 75–76
- CMV. *See* cytomegalovirus
- CNS injury. *See* central nervous system  
 injury
- cocaine abuse, 70
- complete hydatidiform mole, 24–30
- ancillary diagnosis for, 27–28
- with immunohistochemical  
 staining, 28
- biparental, 25
- chimerism mechanism, 28
- CHM, 265–66
- clinical context for, 24–25
- with coexistent fetus, 265–66
- ancillary diagnostic testing, 265
- clinical context, 265
- features, 265, 266
- pathogenesis for, 265
- prognosis for, 265–66
- cytotrophoblast, 24
- differential diagnosis for, 27
- features, 25–27, 36
- FIGO 2000 scoring system, 29
- mosaicism mechanism, 28
- pathogenesis of, 25
- pathology of, 24
- prognosis for, 28–30
- syncytiotrophoblast, 24
- with twin gestation, 31–32
- ancillary diagnosis of, 32
- clinical context for, 31
- differential diagnosis of, 32
- features of, 31–32
- pathogenesis for, 31
- villous mesenchyme, 24
- congenital annular bands. *See*  
 amnionic band syndrome
- congenital annular effects. *See*  
 amnionic band syndrome
- congenital band syndrome. *See*  
 amnionic band syndrome
- congenital transverse effects. *See*  
 amnionic band syndrome
- constriction rings. *See* amnionic band  
 syndrome
- cornual ectopic pregnancy, 277–78
- features, 279
- pathogenesis for, 278
- corticosteroids, for active maternal  
 disease processes, 12–13
- CSP. *See* cesarean scar pregnancy
- CTB. *See* cytotrophoblast
- cytomegalovirus (CMV), 119, 120. *See*  
*also* chronic villitis
- cytotrophoblast (CTB)
- invaginations of, 1
- mononuclear, 1
- in placental development, 1–2, 4–5
- as trophoblast stem cell, 1–2
- cytotrophoblasts, 24
- DCH. *See* diffuse chorioamnionic  
 hemosiderosis
- decidual arteriopathy, 53–55
- clinical context, 53
- diagnosis for, 55
- features, 54–55
- preeclampsia, 54
- pathogenesis for, 53–54
- prognosis for, 55
- decidual vasculitis, 14
- deciduitis, chronic, 147–49
- clinical context, 147
- features, 148–49
- pathogenesis for, 147–48
- preterm labor, 149
- prognosis for, 149
- dehiscence. *See* uterine rupture
- delayed villous maturation (DVM),  
 83–85, 93, 100, 101. *See also*  
 fetal vascular malperfusion
- clinical context, 83
- CNS injury and, 323–24
- diagnosis of, 85
- features, 83–85
- pathogenesis, 83
- prognosis for, 85
- delivered placenta, 285–86
- developmentally abnormal early  
 pregnancy loss, 10–11
- clinical context for, 10
- defined, 10
- diagnosis and prognosis, 11
- features, 10–11
- pathogenesis for, 10
- developmentally normal early  
 pregnancy loss, 11–12
- clinical context, 11
- features of, 11–12
- pathogenesis of, 11
- prognostic implications, 12
- diabetes
- fetal death from, 319–20
- gestational, 83, 193
- pregestational, 62
- pregnancy losses from, 328
- diabetes-associated pregnancy losses,  
 328
- diandric uniparental disomy of  
 chromosome 11, 25
- dichorionic twins
- fetal growth discordance, 264
- ancillary diagnostic testing, 264
- clinical context, 264
- features, 264
- pathogenesis for, 264
- prognosis for, 264
- placental development, 262–63
- ancillary diagnostic testing for,  
 263
- clinical context, 262
- features, 262–63
- mean weights and percentiles for,  
 338
- pathogenesis for, 262
- prognosis for, 263
- diffuse chorangiomatosis, 82–83
- diffuse chorioamnionic hemosiderosis  
 (DCH), 73, 75–76
- diffuse chronic villitis, 119
- diffuse distal villous hypoplasia. *See*  
 distal villous hypoplasia
- diffuse villitis of unknown etiology  
 (VUE), 142. *See also* high grade  
 VUE
- diffuse villous edema, 111–12
- clinical context, 111
- features, 111, 112
- pathogenesis for, 111
- prognosis for, 112
- diffuse VUE, 142
- digynic triploidy, 21
- dilation and curettage, 285

- discordant severe IUGR, 264. *See also* fetal growth discordance
- distal villous hypoplasia, 58–60  
clinical context, 58  
early onset IUGR, 58  
defined, 58  
diagnosis, 59  
features, 59, 60  
gross, 59  
microscopic, 59  
pathogenesis for, 58–59  
angiogenic factors, 58  
in first trimester, 58  
prognosis for, 60
- distal villous immaturity, 83–85. *See also* delayed villous maturation
- distal villous vascular pattern, abnormal, 85–87. *See also* dysmorphic villi
- dizygotic twins, 262
- DVM. *See* delayed villous maturation
- dysmorphic villi, 19, 85–87  
Beckwith-Wiedemann syndrome and, 85  
clinical context, 85  
diagnosis for, 87  
early pregnancy loss without, 16–17  
clinical context, 16  
pathogenesis of, 16  
features, 85–87  
pathogenesis for, 85  
prognosis for, 87  
trophoblast inclusions and, 85–87
- early amnion rupture. *See* amnionic band syndrome
- early amnion rupture sequence. *See* amnionic band syndrome
- early pregnancy loss (EPL), with abnormal karyotype  
aneuploidies in, 16  
defined, 16  
with dysmorphic features, 17–19  
abnormal vascular patterning, 18  
clinical context, 17  
features of, 17–19  
pathogenesis, 17  
prognosis for, 19  
without dysmorphic villi, 16–17  
clinical context, 16  
pathogenesis of, 16  
features, 16–17  
first trimester chorionic sac, 17  
prognosis for, 17
- early pregnancy loss (EPL), with normal karyotype  
active maternal disease processes, 12–14  
clinical context, 12–13  
features of, 13–14
- management options, 13  
noninfectious, 12–13  
pathogenesis for, 13  
prognosis for, 14
- categories of, 9
- chronic histiocytic intervillitis, 13
- decidual vasculitis, 14  
defined, 9
- developmentally abnormal, 10–11  
clinical context for, 10  
defined, 10  
diagnosis and prognosis, 11  
features, 10–11  
pathogenesis for, 10
- developmentally normal, 11–12  
clinical context, 11  
features of, 11–12  
pathogenesis of, 11  
prognostic implications, 12
- embryonic, 9
- fetal, 9
- fresh intervillous hemorrhage, 12  
guidelines for, 9  
first trimester chorionic sac, 9, 10
- lymphoplasmacytic deciduitis, 13
- massive perivillous fibrin deposition, 13
- spontaneous, 11–12
- VUE, 14
- ectopic pregnancies, 276–80  
abdominal, 277  
features, 279  
pathogenesis for, 278  
ancillary diagnostic testing for, 279
- cervical, 277  
features, 278–79, 280  
pathogenesis for, 278
- clinical context, 276
- cornual, 277–78  
features, 279  
pathogenesis for, 278
- defined, 276
- implantation sites, 277
- ovarian, 277  
features, 278–79, 281  
pathogenesis for, 278
- prognosis for, 279
- risk factors for, 277
- tubal, 276–77  
features, 278, 279, 280  
pathogenesis for, 278
- edema. *See also* villous edema  
defined, 109
- hydrops placentalis, 109–11  
etiology of, 109  
features, 109–10  
fetal death, 319  
pathogenesis for, 109  
prognosis for, 109–10
- embryonic early pregnancy loss, 9
- eosinophilic/T cell chorionic vasculitis, 149–50  
clinical context, 149  
features, 149–50  
pathogenesis for, 149
- epithelioid trophoblastic tumor (ETT), 41–43  
clinical context for, 41  
diagnostic approaches, 42  
features of, 41–42  
pathogenesis of, 41  
prognosis of, 42–43
- EPL. *See* early pregnancy loss
- erythroblastosis fetalis, 208
- E/TCV. *See* eosinophilic/T cell chorionic vasculitis
- ETT. *See* epithelioid trophoblastic tumor
- EVT. *See* extravillous trophoblast
- exaggerated implantation site, 34–36  
ancillary diagnosis of, 36  
clinical context for, 34  
differential diagnosis of, 36  
features of, 35–36  
MelCam expression, 34, 35  
pathogenesis for, 34–35  
prognosis for, 36
- excessive immature extravillous trophoblast, 51–53  
clinical context for, 51  
diagnosis for, 53  
features, 51–53  
nuclear atypia, 52  
pathogenesis for, 51  
chorionic cysts, 51, 52–53  
membrane microcysts, 53  
preeclampsia, 51  
prognosis for, 53
- excessive implantation site  
trophoblastic giant cells, 49–51.  
*See also* superficial implantation site
- extravillous trophoblast (EVT). *See also* excessive immature extravillous trophoblast  
implantation and differentiation of, 2–4  
IUGR and, 4  
physiologic change, 4  
physiologic conversion, 4  
regulatory T cells, 4  
subtypes, 6–7  
terminology, 6–7
- interstitial, 2–4
- mature, 2
- morbidly adherent placenta and, 284–85, 287–89
- superficial implantation site and extravillous trophoblast failure, 49

## Index

- extravillous trophoblast (EVT) (cont.)  
 invasive extravillous trophoblast, 50  
 mature extravillous trophoblast, 50  
 transitional, 51–53
- extravillous trophoblastic lineage, 34–43. *See also* placental site trophoblastic tumor
- epithelioid trophoblastic tumor, 41–43  
 clinical context for, 41  
 diagnostic approaches, 42  
 features of, 41–42  
 pathogenesis of, 41
- exaggerated implantation site reaction, 34–36  
 ancillary diagnosis of, 36  
 clinical context for, 34  
 differential diagnosis of, 36  
 features of, 35–36  
 MelCam expression, 34, 35  
 pathogenesis for, 34–35  
 prognosis for, 36
- placental site nodule, 36–38  
 ancillary diagnosis of, 38  
 clinical context for, 37  
 differential diagnosis of, 37–38  
 features of, 37, 38  
 pathogenesis of, 37  
 prognosis for, 38
- post-cesarean epithelioid trophoblastic lesion, 38–39  
 clinical context for, 38  
 diagnostic approaches to, 38  
 features of, 38  
 pathogenesis for, 38  
 prognosis of, 39
- fetal death. *See also* chronic events  
 acute events for, 317–18  
 atraumatic acute placental abruption, 317–18  
 spontaneous umbilical cord rupture, 318  
 uterine rupture, 317–18
- catastrophic events and, 316–17  
 ruptured vasa previa, 317  
 traumatic acute placental abruption, 317  
 umbilical cord prolapse, 317
- defined, 316
- diabetes-associated, 319–20
- pathologic processes, 316
- subacute events for, 318  
 amniotic fluid infection, 318  
 fetal maternal hemorrhage, 318  
 fetal vascular malperfusion, 318
- fetal early pregnancy loss, 9
- fetal growth discordance  
 in dichorionic twins, 264  
 ancillary diagnostic testing, 264  
 clinical context, 264  
 features, 264  
 pathogenesis for, 264  
 prognosis for, 264
- in monochorionic twins, 253–54  
 clinical context, 253  
 features, 253–54, 255  
 pathogenesis for, 253  
 prognosis for, 254
- fetal growth restriction (FGR), 157, 312–14  
 features, 313–14  
 pathogenesis for, 313  
 prognosis for, 314  
 risk factors for, 313
- fetal maternal hemorrhage, 318
- fetal membranes, 5–6
- fetal metastatic malignancies, 223–25  
 clinical context, 224  
 features, 224
- leukemias  
 AML, 225  
 B cell, 224  
 neuroblastomas in, 224  
 pathogenesis for, 224  
 prognosis for, 225  
 transient abnormal myelopoiesis (TAM), 224
- fetal vascular integrity. *See also* edema; hemorrhage  
 causes of, 104  
 villous edema, 104
- fetal vascular malperfusion (FVM)  
 ancillary testing, 94  
 grading considerations, 94  
 clinical context, 93–94  
 fetal/neonatal associations, 94  
 predisposed conditions, 93  
 CNS injury and, 323  
 defined, 93  
 fetal death and, 318  
 global, 101  
 gross features, by location, 94–96  
 capillary vessels, 96  
 placental muscular vessels, 95–97  
 umbilical cord, 94–95, 96  
 microscopic features, by location, 96–101  
 capillary vessels, 98–101  
 placental muscular cells, 96–99  
 umbilical cord, 96, 97  
 pathogenesis for, 94  
 patterns of, 101  
 prognosis for, 101  
 recurrent pregnancy loss, 329  
 segmental, 101
- fetal vascular tears, 105–7  
 clinical context, 106  
 features, 106–7  
 pathogenesis, 106  
 prognosis for, 107  
 ruptured vasa previa, 106  
 stillbirth as result of, 107  
 in umbilical cord, 106, 107
- fetal vasculitis, 201
- fetal villous tree development, 4–5
- fetal-stromal vascular developmental abnormalities, 79. *See also specific abnormalities*
- fetoscopic laser occlusion of communicating vessels, 247–49. *See also* laser-treated monochorionic twin placenta
- fetus papyraceus, 266  
 clinical context, 266–67  
 features, 268
- FGR. *See* fetal growth restriction
- fibrin plaque. *See* subchorionic intervillous thrombus
- fibrinoid necrosis, 49–50, 53–55. *See also* decidual arteriopathy  
 accelerated villous maturation and, 63–64
- fibrinoid replacement, 49–50
- FIGO 2000 scoring system, 29
- FIGO/WHO scoring system, 40–41
- first trimester chorionic sac, in early pregnancy loss, 9, 10  
 with abnormal karyotype, 17
- first trimester chorionic villi, 4–5
- foam cells, 53–55. *See also* decidual arteriopathy
- focal distal villous hypoplasia. *See* distal villous hypoplasia
- focal placenta accreta, 283
- fragmented placenta. *See* retained products of conception
- fresh intervillous hemorrhage, 12
- FVM. *See* fetal vascular malperfusion
- galactosialidosis, 235, 237
- GBS. *See* Group B streptococci
- GCM1. *See* Glial Cells Missing-1
- gestational diabetes, 83, 193
- gestational trophoblastic disease, 21. *See also* extravillous trophoblastic lineage; villous trophoblastic lineage
- giant cell villitis, 120  
 acute chorioamnionitis, 123–24
- giant cells. *See* excessive implantation site trophoblastic giant cells; placental site giant cells
- giant chorangioma, 320
- giant congenital melanocytic nevus (GCMN), 225–26

- ancillary diagnostic testing for, 226  
 clinical context, 225  
 features, 226  
 pathogenesis for, 225–26  
 prognosis for, 226  
 Glial Cells Missing-1 (GCM1), 5  
 global partial fetal vascular malperfusion, 101  
 global/partial maternal vascular malperfusion, 62–65. *See also* accelerated villous maturation  
 GM 1-gangliosidosis, 235  
 Group B streptococci (GBS), 117  
  
 HBV. *See* Hepatitis B virus  
 HCA. *See* histologic chorioamnionitis  
 HCV. *See* Hepatitis C virus  
 HELLP syndrome, 193  
 hematogenously spread infections. *See* chronic villitis; villitis  
 hematoma. *See also* subchorionic intervillous thrombus  
   basal intervillous thrombus, 192  
   infarction, 66–67  
     clinical context, 66  
     features, 67  
     multiple, 67  
     pathogenesis for, 66–67  
     prognosis for, 67  
     stillbirth and, 67  
   rounded placental, 66–67  
   with umbilical cord, 170–71  
 hemorrhage. *See also* postpartum hemorrhage  
   fetal maternal, 318  
   fetal vascular tears, 105–7  
     clinical context, 106  
     features, 106–7  
     pathogenesis, 106  
     prognosis for, 107  
     ruptured vasa previa, 106  
     stillbirth as result of, 107  
   in umbilical cord, 106, 107  
 intervillous thrombus, 104–5  
   clinical context, 104  
   features, 104, 105  
   pathogenesis for, 104  
   prognosis for, 105  
   with surrounding villous infarction, 66–67  
 intravillous hemorrhage, 107–8  
   clinical context, 108  
   features, 108  
   pathogenesis for, 108  
   prognosis for, 108  
 products of conception and, 292–93  
   clinical context, 292–93  
   features, 293  
   pathogenesis for, 293  
   retroplacental, 324  
  
 heparin, for active maternal disease processes, 12–13  
 hepatic heterotopia, 230–31  
   ancillary diagnostic testing for, 230  
   clinical context, 230  
   features, 230, 231  
   pathogenesis, 230  
   prognosis for, 230–31  
 Hepatitis B virus (HBV), 115  
 Hepatitis C virus (HCV), 115  
 Herpes simplex virus (HSV), 115  
 heterotopia  
   adrenocortical, 231–32  
     ancillary diagnostic testing for, 232  
     clinical context, 231  
     features, 231, 232  
     pathogenesis for, 231  
     prognosis for, 232  
   hepatic, 230–31  
     ancillary diagnostic testing for, 230  
     clinical context, 230  
     features, 230, 231  
     pathogenesis, 230  
     prognosis for, 230–31  
   high grade VUE, 143  
   histiocytic intervillitis, chronic (CHI), 13  
     clinical context, 152  
     diagnosis for, 153, 154  
     features, 153  
     fetal death and, 319  
     mixed, 153  
     pathogenesis for, 152–53  
     prognosis for, 153  
     recurrent pregnancy loss from, 327, 328  
   histologic chorioamnionitis (HCA), 307–8  
     CNS injury, 323  
   HPV. *See* human papilloma virus  
   HSV. *See* Herpes simplex virus  
   human papilloma virus (HPV), 123  
   hyaline membrane disease, 112  
   hyalinized villi. *See* early pregnancy loss  
   hydatidiform mole. *See* androgenetic biparental mosaic chimerism; complete hydatidiform mole; partial hydatidiform mole  
   hydropic phenotype, 26–27  
   hydropic villi. *See* early pregnancy loss  
   hydrops placentalis, 109–11  
     etiology of, 109  
     features, 109–10  
     fetal death, 319  
     pathogenesis for, 109  
     prognosis for, 109–10  
   hypercoiled umbilical cord, 169–70  
  
 hyperprostaglandin E syndrome, 239  
 hypertension, maternal, 70, 193  
 hypertrophic arteriopathy, 53–55. *See also* decidual arteriopathy  
 hypocoiled umbilical cord, 169–70  
 hypoplastic umbilical artery, 171–73  
 hysterectomy  
   after placenta delivery, 286, 287  
   for PSTT, 39  
   specimen with placenta in situ, 286–87, 288, 289  
   with uterine atony, 299  
   uterine rupture and, 297  
  
 I cell disease, 235  
 ICM. *See* inner cell mass  
 idiopathic chronic inflammatory lesions, 308–9  
 in vitro fertilization (IVF), 266, 268–69  
 increased circulating fetal nucleated red blood cells (NRBCs)  
   clinical context for, 206  
   diagnosis for, 208–11  
     ancillary testing in, 211  
     differential, 208–11  
     erythroid precursors, 210  
   features, 207–8  
   normoblastemia and, 207–8  
     causes of, 209  
     dyserythropoietic, 208  
     erythroblastosis fetalis and, 208  
     stem vessel, 207  
     types of, 210–11  
     umbilical cord, 207  
   pathogenesis, 206–7  
   prognosis for, 211  
   relative to absolute, translation formulas for, 206  
   threshold values for, 210  
   indicated preterm birth (IPB), 307  
   infant sialic acid storage disorder, 235  
   infarction-hematoma, 66–67, 192–95.  
     *See also* rounded intraplacental hematoma  
     clinical context, 66  
     features, 67  
     multiple, 67  
     pathogenesis for, 66–67  
     prognosis for, 67  
     stillbirth and, 67  
   inner cell mass (ICM), 1  
   intermediate trophoblast, increased immature, 51–53. *See also* excessive immature extravillous trophoblast  
   interstitial extravillous trophoblast, 2–4  
   intervillositis  
     chronic histiocytic, 13  
     clinical context, 129

## Index

- intervillositis (cont.)  
 diagnosis, 130  
 features, 129–30  
 prognosis for, 130  
 VUE with, 120
- intervillous fibrin, increased, 62–65, 130–31. *See also* accelerated villous maturation
- intervillous thrombus (IVT), 104–5.  
*See also* subchorionic intervillous thrombus  
 clinical context, 104  
 features, 104, 105  
 pathogenesis for, 104  
 prognosis for, 105  
 with surrounding villous infarction, 66–67
- intrafunicular hemorrhage, 170–71
- intramural fibrin deposition, 93. *See also* fetal vascular malperfusion
- intramural lipid laden macrophages, 53–55. *See also* decidual arteriopathy
- intraplacental choriocarcinoma, 33–34  
 clinical context for, 33  
 differential diagnosis of, 34  
 features for, 33–34  
 pathogenesis for, 33  
 prognosis for, 34
- intraplacental hemorrhages, atypical  
 basal intervillous thrombus, 192  
 basal plate plaque, 195–97  
 clinical context, 196  
 differential diagnosis for, 196  
 features, 196  
 pathogenesis for, 196  
 prognosis for, 197
- massive subchorial thrombohematoma, 188–90  
 clinical context, 188  
 defined, 188  
 diagnosis of, 189–90  
 features, 189  
 pathogenesis, 188–89  
 prognosis for, 190
- rounded intraplacental hematoma, 192–95  
 clinical context for, 193  
 differential diagnosis for, 194–95  
 features, 193–94  
 lesions and, 194  
 pathogenesis for, 193  
 prognosis for, 195
- subchorionic intervillous thrombus, 190–92  
 clinical context, 191  
 differential diagnosis of, 192  
 features, 191  
 pathogenesis, 191  
 prognosis for, 192
- intraplacental trophoblast islands, 6
- intrauterine fetal death (IUFD), 64
- intrauterine growth restriction (IUGR), 4, 137, 193  
 discordant severe, 264  
 early onset, 58  
 fetal growth restriction, 157, 312–14  
 features, 313–14  
 pathogenesis for, 313  
 prognosis for, 314  
 risk factors for, 313
- intravillous hemorrhage, 107–8  
 clinical context, 108  
 features, 108  
 pathogenesis for, 108  
 prognosis for, 108
- invasive hydatidiform mole, 30–31  
 ancillary diagnosis of, 30  
 clinical context for, 30  
 differential diagnosis of, 30  
 features of, 30  
 prognosis of, 30–31
- IPB. *See* indicated preterm birth
- irregular placental contour, 161–63
- irregular villous contour, 17–19, 85–87. *See also* dysmorphic villi; early pregnancy loss
- isthmocele pregnancy. *See* cesarean scar pregnancy
- IUFD. *See* intrauterine fetal death
- IUGR. *See* intrauterine growth restriction
- IVF. *See* in vitro fertilization
- IVH. *See* intravillous hemorrhage
- IVT. *See* intervillous thrombus
- labor. *See* preterm labor; spontaneous preterm birth
- large for gestational age (LGA) placenta, 157, 158, 159
- laser ablation. *See* laser-treated monochorionic twin placenta
- laser-treated monochorionic twin placenta, 247–49  
 ancillary diagnostic testing for, 248–49  
 clinical context, 247–48  
 features, 248, 249  
 prognosis for, 249
- late amnion rupture. *See* amnion rupture
- leiomyomas, implantation over, 70
- lesions, inflammatory. *See also* capillary-vascular lesions  
 chronic chorioamnionitis, 139, 142, 145–47  
 clinical context, 145  
 diagnosis of, 146  
 features, 145–46  
 pathogenesis for, 145
- prognosis for, 146–47  
 staging of, 146, 147
- chronic deciduitis, 147–49  
 clinical context, 147  
 features, 148–49  
 pathogenesis for, 147–48  
 preterm labor, 149  
 prognosis for, 149
- in CNS injury, 323–24
- eosinophilic/T cell chorionic vasculitis, 149–50  
 clinical context, 149  
 features, 149–50  
 pathogenesis for, 149
- in placental infections, 307–9  
 acute marginal abruption, 308  
 chronic abruption, 308  
 histologic chorioamnionitis, 307–8  
 idiopathic chronic, 308–9  
 maternal vascular malperfusion, 308
- rounded intraplacental hematoma and, 194
- umbilical cord, 173–76  
 clinical context, 173  
 features, 174–75  
 pathogenesis for, 173–74  
 prognosis for, 176
- leukemia, 222  
 AML, 225  
 B cell, 224
- LGA placenta. *See* large for gestational age placenta
- Listeria monocytogenes*, 117–18
- long umbilical cord, 167–68
- lymphomas, 222  
 non-Hodgkin lymphoma, 222
- lymphoplasmacytic deciduitis, 13, 147–49. *See also* deciduitis
- lysosomal storage disease (LSD), 235–38  
 ancillary diagnostic testing, 236–37  
 clinical context, 235  
 features, 235–36  
 pathogenesis for, 235  
 prognosis for, 237  
 specific disorders, 235
- MAP. *See* morbidly adherent placenta
- marginal abruption  
 acute, 72–75  
 clinical context, 72  
 diffuse chorioamnionic hemosiderosis and, 73, 75–76  
 features, 73  
 pathogenesis for, 73  
 prognosis for, 73  
 chronic, 75–76  
 clinical context, 75

- features, 75–76  
 pathogenesis for, 75  
 prognosis for, 76
- massive perivillous fibrin deposition (MPFD), 13, 130–31, 181–84  
 ancillary testing for, 183  
 clinical context, 181  
 features, 182–83  
 fetal death and, 319  
 pathogenesis for, 181–82  
 prognosis for, 183–84
- massive subchorial thrombohematoma, 188–90  
 clinical context, 188  
 defined, 188  
 diagnosis of, 189–90  
 ancillary testing in, 190  
 differential, 189–90  
 features, 189  
 pathogenesis, 188–89  
 prognosis for, 190
- maternal floor infarct (MFI), 130–31, 181–84  
 ancillary testing for, 183  
 clinical context, 181  
 features, 182–83  
 fetal death and, 319  
 pathogenesis for, 181–82  
 prognosis for, 183–84  
 recurrent pregnancy loss and, 328
- maternal hypertension. *See* hypertension
- maternal metastatic malignancies, 220–25  
 ancillary diagnostic testing for, 223  
 breast cancer, 222, 223  
 cervical cancer, 223  
 clinical context, 220  
 features, 220–21  
 hematological, 222  
 lung cancer, 222–23  
 lymphomas, 222  
 melanomas, 221–22  
 non-Hodgkin lymphoma, 222  
 pathogenesis, 220  
 prognosis for, 223
- maternal vascular abnormalities, 49–78. *See also specific abnormalities*
- maternal vascular integrity, 70. *See also* abruptio placentae; marginal abruption
- maternal vascular malperfusion (MVM), 308, 319. *See also* accelerated villous maturation; villous infarcts  
 CNS injury, 323  
 complete/segmental, 65–66  
 global/partial, 62–65  
 infarction-hematoma, 66–67  
 clinical context, 66  
 features, 67  
 multiple, 67  
 pathogenesis for, 66–67  
 prognosis for, 67  
 stillbirth and, 67
- recurrent pregnancy loss and, 328
- villous infarcts, remote and recent, 65–66  
 clinical context, 65  
 features of, 65–66  
 multiple, 65  
 pathogenesis for, 65  
 prognosis for, 66
- maturation defect, 83–85. *See also* delayed villous maturation
- mature extravillous trophoblast, 2
- MC. *See* multifocal chorangiomas
- meconium effects  
 clinical context, 199  
 CNS injury and, 324  
 decidual, 202  
 defined, 199  
 diagnosis for, 202–3  
 ancillary testing in, 203  
 differential, 202–3  
 discharge-to-delivery intervals, 204  
 features, 199–200, 201  
 particulate, 201  
 pathogenesis for, 199  
 prognosis for, 203–4  
 risk factors, 200  
 superficial, 202  
 Wharton's jelly and, 203
- meconium myonecrosis, 200–2  
 features, 203  
 fetal vasculitis, 201  
 normoblastemia, 201–2  
 reactive amnion hyperplasia, 201
- MelCam protein molecule, 34, 35
- membrane rupture. *See* amnionic band syndrome
- membranous microcysts, 51–53. *See also* excessive immature extravillous trophoblast  
 excessive immature extravillous trophoblast and, 53
- mesenchymal dysplasia, 320
- metastatic malignancies, 220–25. *See also* fetal metastatic malignancies; maternal metastatic malignancies
- metastatic tumors, 220. *See also* fetal metastatic malignancies; maternal metastatic malignancies; *specific malignancies*
- MFI. *See* maternal floor infarct
- microcysts. *See* basal plate microcysts; membranous microcysts
- microinfarcts, 62–65. *See also* accelerated villous maturation
- mineralization. *See* villous trophoblast basement membrane
- mixed chronic histiocytic intervillitis, 153
- molar pregnancy. *See* complete hydatidiform mole; partial hydatidiform mole
- monoamniotic placentation, twinning and  
 clinical context, 254–57  
 features, 255–56  
 umbilical cord entanglement, 256
- incidence rates for, 255  
 pathogenesis for, 255  
 prognosis for, 256
- twin anemia-polycythemia sequence (TAPS) and, 255
- twin reversed arterial perfusion (TRAP) syndrome and, 255
- twin-to-twin transfusion syndrome (TTTS) and, 254–55
- monochorionic diamniotic twins. *See also* laser-treated monochorionic twin placenta; twin anemia-polycythemia sequence; twin reversed arterial perfusion syndrome; twin-to-twin transfusion syndrome
- fetal growth discordance, 253–54  
 clinical context, 253  
 features, 253–54, 255  
 pathogenesis for, 253  
 prognosis for, 254
- monozygotic twinning, 242  
 pathogenesis for, 241–42
- placental development, 241–44  
 ancillary diagnostic testing for, 244  
 atypical twinning, 242  
 chorionicity and, 241  
 clinical context for, 241  
 features, 242–44  
 prognosis for, 244
- monochorionic twins. *See* fetal growth discordance
- mononuclear CTBs (cytotrophoblast), 1
- monozygotic twinning, 242
- monozygotic twins, 262
- morbidly adherent placenta (MAP). *See also* placenta accreta
- Asherman syndrome and, 284  
 clinical context, 283–84  
 complications of, 284  
 defined, 283  
 diagnosis for, 284  
 ancillary testing in, 289

## Index

- morbidly adherent placenta (cont.)  
   extravillous trophoblast and,  
     284–85, 287–89  
   features, 285–89  
     delivered placenta, 285–86  
     dilation and curettage, 285  
     hysterectomy after placenta  
     delivery, 286, 287  
     hysterectomy specimen with  
     placenta in situ, 286–87, 288,  
     289  
   pathogenesis for, 284–85  
   pathologic staging of, 283  
   placenta accreta and, 283–89  
   prognosis for, 289  
 mosaicism mechanism, 28  
 mucopolipidosis type I, 235  
 mucopolipidosis type II, 235  
 multifocal chorangiomas (MC),  
   82–83  
   Beckwith-Wiedemann syndrome, 83  
   clinical context, 82  
   features, 82–83  
   fetal death and, 320  
   pathogenesis for, 82  
   prognosis for, 83  
 multifocal low-grade VUE, 139  
 multilobed placenta, 161–63  
 multiple gestations. *See* dichorionic  
   twins; monozygotic twins; triplet  
   pregnancies  
 mural hypertrophy, 53–55. *See also*  
   decidual arteriopathy  
 MVM. *See* maternal vascular  
   malperfusion  
 myometrial fibers adherent to the basal  
   plate (BPMYO), 290–91  
   clinical context for, 290  
   features, 290, 291  
   prognosis for, 290–91  
  
 necrotizing acute chorioamnionitis,  
   125  
 necrotizing funisitis, 124, 125  
 neuroblastomas, 224  
 nodular/stunted embryos, 16–17. *See*  
   *also* early pregnancy loss  
 non-Hodgkin lymphoma, 222  
 noninfectious active maternal disease  
   processes, 12–13  
 non-infectious chronic villitis, 319  
 nonspecific trophoblast hyperplasia.  
   *See* trophoblast hyperplasia  
 normoblastemia  
   meconium myonecrosis and, 201–2  
   mild, 210  
   moderate, 210–11  
   NRBCs and, 207–8  
   causes of, 209  
  
 dyserythropoietic, 208  
 erythroblastosis fetalis and, 208  
   stem vessel, 207  
   types of, 210–11  
   umbilical cord, 207  
   severe, 210–11  
 NRBCs. *See* increased circulating fetal  
   nucleated red blood cells  
 nuclear atypia, 52  
  
 obliterative villitis, 119  
 occult placenta accreta. *See* myometrial  
   fibers adherent to the basal plate  
 oligohydramnios, 70  
 omphalomesenteric duct cyst, 173–76  
 ovarian ectopic pregnancy, 277  
   features, 278–79, 281  
   pathogenesis for, 278  
  
 parentally inherited aneuploidy, 327  
 partial hydatidiform mole, 21–24  
   ancillary diagnosis for, 23–24  
   clinical context for, 21  
   differential diagnosis for, 22–23  
   features of, 21–22, 23  
   pathogenesis of, 21  
   prognosis for, 24  
   triploidy and, 21  
 partial placenta accreta, 283  
 parvovirus, 131  
 patchy villous edema, 112  
   features, 112  
   prognosis for, 112  
 patchy VUE, 138  
 perivasculitis, chronic, 53–55. *See also*  
   decidual arteriopathy  
 periventricular leukomalacia, 247  
 perivillous fibrin deposition, 141. *See*  
   *also* maternal floor infarct  
   localized (perivillous fibrin plaque),  
   184–85  
   clinical context, 184  
   features, 184, 185  
   pathogenesis for, 184  
 MPFD, 13, 130–31, 181–84  
   ancillary testing for, 183  
   clinical context, 181  
   features, 182–83, 201  
   fetal death and, 319  
   pathogenesis for, 181–82  
   prognosis for, 183–84  
 perivillous fibrin plaque (PFP). *See*  
   perivillous fibrin deposition  
 persistent muscularization of basal  
   plate arteries, 49–51. *See also*  
   superficial implantation site  
 persistent right umbilical vein, 171–73  
 PFP. *See* perivillous fibrin deposition  
 placenta, development of, 1–2. *See also*  
   abnormal placental location;  
   dichorionic twins; fetal  
   metastatic malignancies;  
   maternal metastatic  
   malignancies; monozygotic  
   diamniotic twins; small for  
   gestational age  
   abnormal contours in, 161–63  
   clinical context, 162  
   diagnosis for, 163  
   features, 162–63  
   pathogenesis for, 162  
   prognosis for, 163  
   abnormalities in, 159–61  
   clinical context, 159  
   features, 160–61  
   pathogenesis for, 159–60  
   prognosis for, 161  
   bilobate placenta, 163–64  
   clinical context, 163  
   features, 164  
   pathogenesis for, 163–64  
   chorionic villi, 4, 5  
   abnormalities in, 5  
   first trimester, 4–5  
   GCM1, 5  
   syncytiotrophoblast, 4–5  
   tertiary, 5  
   chorionicity and, 241  
   CTB (cytotrophoblast), 1–2, 4–5  
   EVT (extravillous trophoblast) and,  
     implantation and  
     differentiation of, 2–4  
   IUGR and, 4  
   physiologic change, 4  
   physiologic conversion, 4  
   regulatory T cells, 4  
   subtypes, 6–7  
   terminology, 6–7  
   fetal membranes, 5–6  
   fetal villous tree development, 4–5  
   fetal-placental weight, by gestational  
   age, 337, 342–43  
   gross examination of, 333–35  
   ICM (inner cell mass), 1  
   intraplacental trophoblast islands, 6  
   knowledge gaps for, 7  
   LGA, 157, 158, 159  
   shape of, 161–64  
   size in, 157–61  
     abnormalities in, 159–61  
   standard deviation for placental  
   weights, 336, 342–43  
   stillbirth by time interval, 341  
   TE (trophoblast) cells, 1  
   vascular integrity in, 70  
   placenta accreta, 283–89  
   placenta membranacea, 163–64  
   clinical context, 163  
   features, 164  
   pathogenesis for, 163–64

- placenta previa, 275–76  
 clinical context, 275  
 features, 275–76  
 pathogenesis for, 275  
 prognosis for, 276  
 risk factors for, 275
- placental abruption, atraumatic acute, 317–18
- placental attachment disorders. *See* *specific disorders*
- placental bed vascular subinvolution. *See* subinvolution of placental site
- placental hemangiomas, 80–82. *See also* chorangiomas
- placental hydrops. *See* hydrops placentalis
- placental infections, 115. *See also specific infections*  
 silent, 131
- placental mesenchymal dysplasia (PMD), 87–90  
 clinical context, 87  
 diagnosis, 89, 90  
 features, 88–89  
 pathogenesis for, 87–88  
 prognosis for, 90
- placental mosaicism, 62
- placental muscular vessels, with fetal vascular malperfusion  
 gross features, by location, 95–97  
 microscopic features, by location, 96–99
- placental site giant cells, increase in, 49–51. *See also* superficial implantation site
- placental site nodule, 36–38  
 ancillary diagnosis of, 38  
 clinical context for, 37  
 differential diagnosis of, 37–38  
 features of, 37, 38  
 pathogenesis of, 37  
 prognosis for, 38
- placental site trophoblastic tumor (PSTT), 39–41  
 clinical context for, 39  
 diagnostic approaches to, 40  
 features for, 39–40  
 FIGO/WHO scoring system for, 40–41  
 hysterectomy for, 39  
 pathogenesis for, 39  
 prognosis for, 40–41
- placental teratomas. *See* teratomas
- placental vascular anomaly with diffuse mesenchymal stem villous hyperplasia, 87–90. *See also* placental mesenchymal dysplasia
- plaque. *See* basal plate plaque
- plasma cell deciduitis, 139
- PMD. *See* placental mesenchymal dysplasia
- poorly vascularized villi. *See* early pregnancy loss
- post-cesarean epithelioid trophoblastic lesion, 38–39  
 clinical context for, 38  
 diagnostic approaches to, 38  
 features of, 38  
 pathogenesis for, 38  
 prognosis of, 39
- postpartum hemorrhage (PPH)  
 defined, 299  
 etiologies of, 300  
 incidence rates for, 299  
 retained placenta, 301–2  
 clinical context for, 301  
 features, 301  
 pathogenesis for, 301  
 prognosis for, 302  
 subinvolution of placental site, 302–4  
 clinical context, 302  
 diagnostic testing for, 304  
 features, 303–4  
 hysterectomy with, 302  
 pathogenesis for, 302  
 uterine atony, 299–301  
 clinical context, 299  
 features, 299  
 hysterectomy with, 299  
 pathogenesis for, 299  
 prognosis for, 301
- PPROM. *See* preterm premature rupture of the membranes
- preeclampsia, 51, 54, 62, 193
- premature labor. *See* spontaneous preterm birth
- preterm labor, 149, 193
- preterm premature rupture of the membranes (PPROM), 70
- progesterone, for active maternal disease processes, 12–13
- proximal-distal villous discordance, 85–87. *See also* dysmorphic villi
- pseudocysts, 173–76
- pseudo-partial mole, 87–90. *See also* placental mesenchymal dysplasia
- PSTT. *See* placental site trophoblastic tumor
- purulent myometritis, acute, 131
- reactive amnion hyperplasia, 201
- recent villous infarcts. *See* villous infarcts
- recurrent multiple chorangioma syndrome, 80–82. *See also* chorangiomas
- recurrent pregnancy loss  
 anatomic disorders, 327  
 abnormal uterine anatomy, 327, 328–29  
 cervical incompetence, 327  
 diabetes-associated, 328  
 in early pregnancy, chronic histiocytic intervillitis, 328–29  
 from immunologic disorders, 327–28  
 antiphospholipid antibodies, 327–28  
 chronic histiocytic intervillitis, 327  
 in late pregnancy, 328–29  
 chronic histiocytic intervillitis, 328  
 chronic villitis, 328  
 fetal vascular malperfusion and, 329  
 maternal floor infarction, 328  
 maternal vascular malperfusion and, 328  
 multiple chorangioma syndrome and, 329  
 parentally inherited aneuploidy, 327  
 regulatory T cells, 4  
 villitis of unknown etiology (VUE) and, 137, 139
- remote villous infarcts. *See* villous infarcts
- retained placenta, 301–2  
 clinical context for, 301  
 features, 301  
 pathogenesis for, 301  
 prognosis for, 302
- retained products of conception (POC), 292–93  
 clinical context, 292–93  
 features, 293  
 pathogenesis for, 293
- retroplacental hemorrhage, 324
- rounded intraplacental hematoma, 192–95  
 clinical context for, 193  
 differential diagnosis for, 194–95  
 features, 193–94  
 lesions and, 194  
 pathogenesis for, 193  
 prognosis for, 195
- rounded placental hematoma, 66–67. *See also* infarction-hematoma
- ruptured vasa previa, 106, 317
- Salla disease, 235
- segmental/complete fetal vascular malperfusion, 101
- segmental/complete maternal vascular malperfusion, 65–66. *See also* villous infarcts

## Index

- SGA. *See* small for gestational age  
shallow implantation site, 49–51. *See also* superficial implantation site  
short umbilical cord, 167–68  
sialidosis, 235  
silent chorioamnionitis, 124  
single umbilical artery (SUA), 171–73  
  clinical context, 172  
  features, 173  
  pathogenesis for, 172–73  
  prognosis for, 173  
small for gestational age (SGA)  
  clinical context, 312–13  
  defined, 312  
  placental development  
    clinical context for, 157–58  
    diagnosis for, 159  
    features, 158–59  
    fetal growth restriction and, 157  
    pathogenesis for, 158  
    prognosis for, 159  
smooth muscle cells within basal plate.  
  *See* myometrial fibers adherent to the basal plate  
SPB. *See* spontaneous preterm birth  
spontaneous early pregnancy loss, 11–12  
spontaneous preterm birth (SPB), 307  
  risk factors for, 307  
squamous metaplasia, 218, 219  
stem cells, trophoblastic (TSC), 1–2  
stem vessel normoblastemia, 207  
stem vessel obliteration, 93, 99. *See also* fetal vascular malperfusion  
stem villous vascular obliteration, 139–41  
stillbirth, 67  
  acute chorioamnionitis and, 121  
  from fetal vascular tears, 107  
  in triplet pregnancies, 270  
Streeter dysplasia, 214–16. *See also* amniotic band syndrome  
streptococci. *See* Group B streptococci  
stromal nuclear karyomegaly, 17–19.  
  *See also* early pregnancy loss  
stromal-architectural abnormalities.  
  *See also* dysmorphic villi  
  delayed villous maturation, 83–85  
  clinical context, 83  
  CNS injury and, 323–24  
  diagnosis of, 85  
  features, 83–85  
  pathogenesis, 83  
  prognosis for, 85  
  placental mesenchymal dysplasia, 87–90  
    clinical context, 87  
    diagnosis, 89, 90  
    features, 88–89  
    pathogenesis for, 87–88  
    prognosis for, 90  
SUA. *See* single umbilical artery  
subamniotic dissection of vernix caseosa, 216–17. *See also* amnion rupture  
subchorial tuberos hematoma, 188–90. *See also* massive subchorial thrombohematoma  
subchorionic intervillous thrombus, 190–92  
  clinical context, 191  
  differential diagnosis of, 192  
  features, 191  
  pathogenesis, 191  
  prognosis for, 192  
subinvolution of placental site, 302–4  
  clinical context, 302  
  diagnostic testing for, 304  
  features, 303–4  
  hysterectomy with, 302  
  pathogenesis for, 302  
succenturiate lobe, 161–63  
superficial implantation site, 49–51  
  clinical context for, 49  
  diagnosis for, 50–51  
  extravillous trophoblast and  
    failure of, 49  
    invasive, 50  
    mature, 50  
  features for, 49–50  
    fibrinoid necrosis, 49–50  
    fibrinoid replacement, 49–50  
    vascular smooth muscle, 50  
  pathogenesis for, 49  
  prognosis for, 51  
surface epithelial inclusion cyst, 173–76  
syncytial knots, 62–65. *See also* accelerated villous maturation  
syncytiotrophoblast, 4–5, 24  
syphilis, 123  
T cells. *See* eosinophilic/T cell chorionic vasculitis; regulatory T cells  
*T. gondii*, 120–21  
*T. pallidum*, 121–22  
TAM. *See* transient abnormal myelopoiesis  
TAPS. *See* twin anemia-polycythemia sequence  
TE cells. *See* trophoctoderm cells  
Tenney-Parker change, 62–65. *See also* accelerated villous maturation  
teratomas, placental, 232–33  
  clinical context for, 232  
  features, 232–33  
  pathogenesis for, 232  
  prognosis for, 233  
tertiary chorionic villi, 5  
thrombi. *See* basal intervillous thrombus; subchorionic intervillous thrombus  
thrombosis, 93. *See also* fetal vascular malperfusion  
thyroid disease, 70  
tobacco use, 70  
TOPS. *See* twin oligohydramnios-polyhydramnios sequence  
total placenta accreta, 283  
toxoplasmosis, 122  
transient abnormal myelopoiesis (TAM), 224  
transitional extravillous trophoblast, 51–53. *See also* excessive immature extravillous trophoblast  
TRAP. *See* twin reversed arterial perfusion syndrome  
trauma, 70  
triplet pregnancies, 268–70  
  clinical context, 268–69  
  clinical features, 269–70  
  patterns of, 269  
  prognostic implications, 270  
  stillborns in, 270  
triploidy, 21  
trophoctoderm (TE) cells, 1  
trophoblast hyperplasia, nonspecific, 17–19, 85–87. *See also* dysmorphic villi; early pregnancy loss  
trophoblast inclusions, 17–19. *See also* early pregnancy loss  
  dysmorphic villi and, 85–87  
trophoblast islands, 51–53. *See also* excessive immature extravillous trophoblast  
trophoblast stem cells (TSC), 1–2. *See also* extravillous trophoblast  
trophoblastic developmental abnormalities, 49–57. *See also* specific abnormalities  
TSC. *See* trophoblast stem cells  
TTTS. *See* twin-to-twin transfusion syndrome  
tubal ectopic pregnancy, 276–77  
  features, 278, 279, 280  
  pathogenesis for, 278  
tumors. *See* specific tumors  
Turner syndrome, 232  
twin anemia-polycythemia sequence (TAPS), 241, 249–51  
  ancillary diagnostic testing, 251  
  clinical context, 249–50  
  features, 250–51  
  monoamniotic placentation and, 255  
  pathogenesis for, 250  
  prognosis for, 251

- twin birth weight discordance, 264. *See also* fetal growth discordance
- twin gestation, complete hydatidiform mole with, 31–32
- ancillary diagnosis of, 32
- clinical context for, 31
- differential diagnosis of, 32
- features of, 31–32
- pathogenesis for, 31
- twin oligohydramnios-polyhydramnios sequence (TOPS), 245–47, 249. *See also* twin-to-twin transfusion syndrome
- twin reversed arterial perfusion (TRAP) syndrome, 241, 251–53
- acardius acephalus, 252
- ancillary diagnostic testing, 253
- clinical context, 251–52
- features, 252–53, 254
- monoamniotic placentation and, 255
- pathogenesis for, 252
- prognosis for, 253
- twins. *See also* dichorionic twins; fetal growth discordance; monoamniotic placentation; monochorionic diamniotic twins
- atypical, 242
- dizygotic, 262
- monozygotic, 242, 262
- twin-to-twin transfusion syndrome (TTTS), 241, 245–47
- ancillary diagnostic testing, 246–47
- clinical context, 245
- staging in, 245
- features, 246, 247
- laser-treated, 247–49
- laser-treated monochorionic twin placenta, 247–49
- ancillary diagnostic testing for, 248–49
- clinical context, 247–48
- features, 248, 249
- prognosis for, 249
- monoamniotic placentation and, 254–55
- pathogenesis for, 245
- periventricular leukomalacia and, 247
- prognosis for, 247
- type 1 vasa previa, 164–66
- type 2 vasa previa, 161–63
- type 3 vasa previa, 164–66
- umbilical cord
- with acute chorioamnionitis, 121
- surface abscesses, 125
- avulsion of, 170–71
- coiling abnormalities, 169–70
- clinical context, 169
- features, 169–70
- pathogenesis for, 169
- prognosis for, 170
- cord coil index, 340
- cystic and solid lesions, 173–76
- clinical context, 173
- features, 174–75
- pathogenesis for, 173–74
- prognosis for, 176
- developmental abnormalities with, 164–76
- fetal death and, from spontaneous rupture, 318
- with fetal vascular malperfusion
- gross features, by location, 94–95, 96
- microscopic features, by location, 96, 97
- fetal vascular tears in, 106, 107
- by gestational age, 339
- hematoma with, 170–71
- insertion site abnormalities, 164–66
- clinical context, 165–66
- defined, 164–65
- features, 166
- furcate, 165
- pathogenesis for, 166
- peripheral, 165
- prognosis for, 166
- length and thickness abnormalities, 167–68
- clinical context, 167
- features, 167–68
- pathogenesis for, 167
- prognosis for, 168
- loss of integrity, 170–71
- clinical context, 170–71
- surface alterations, 170
- monoamniotic placentation and, 256
- non-membranous, 165, 166
- NRBCs and, 207
- prolapse, 317
- ruptured artery aneurysm, 170–71
- single umbilical artery (SUA), 171–73
- clinical context, 172
- features, 173
- pathogenesis for, 172–73
- prognosis for, 173
- type 2 vasa previa, 164–66
- type 3 vasa previa, 164–66
- Wharton's jelly and, 167–68, 171
- uterine atony, 299–301
- clinical context, 299
- features, 299
- hysterectomy with, 299
- pathogenesis for, 299
- prognosis for, 301
- uterine rupture, 296–98
- ancillary diagnostic testing, 297
- clinical context, 296
- features, 297
- fetal death from, 317–18
- hysterectomy and, 297
- pathogenesis for, 296–97
- prognosis for, 297–98
- risk factors for, 296
- vacuolation of villous trophoblast, 235–38. *See also* lysosomal storage disease
- amniotic, 238
- idiopathic, 237
- immature, 238
- vanishing twin syndrome, 266–68
- clinical context, 266–67
- features, 267–68
- fetus papyraceus, 266
- clinical context, 266–67
- features, 268
- pathogenesis for, 267
- prognosis for, 268
- variable maturation, 83–85. *See also* delayed villous maturation
- vascular ectasia, 93, 96. *See also* fetal vascular malperfusion
- vascular smooth muscle, 50
- villitis, 115. *See also* chronic villitis
- acute, 116–18
- clinical context, 116
- diagnosis, 117–18
- features, 116–17
- GBS, 117
- Listeria monocytogenes*, 117–18
- prognosis, 118
- CNS injury and, 323
- features, 115
- giant cell, 120, 123–24
- HBV and, 115
- HCV and, 115
- HSV and, 115
- obliterative, 119
- villitis of unknown etiology (VUE). *See also* lesions
- chronic chorioamnionitis and, 139, 142
- clinical context, 137
- common findings with, 139–41
- diagnosis of
- ancillary testing in, 143
- differential, 141–43
- diffuse, 142
- eosinophilic/T cell chorionic vasculitis and, 139
- features, 138, 139, 140
- fetal death and, 319
- grading of, 138–39
- high grade, 143

## Index

- villitis of unknown etiology (cont.)  
 IUGR and, 137  
 multifocal low-grade, 139  
 patchy, 138  
 pathogenesis for, 137–38  
   regulatory T cell subtypes, 137  
 perivillous fibrin deposition and, 141  
 pitfalls of, 141–43  
 plasma cell deciduitis and, 139  
 prognosis for, 143  
 stem villous vascular obliteration  
   and, 139–41  
 subtypes, 138, 140, 141  
   basal chronic, 142  
 villous agglutination and infarction  
   and, 141
- villous agglutination, 62–65. *See also*  
 accelerated villous maturation
- villous agglutination and infarction, 141
- villous chorangiosis, 79–80  
 Beckwith-Wiedemann syndrome  
   and, 80  
 clinical context, 79  
 diagnosis of, 80  
 features, 80  
 pathogenesis for, 79–80  
 prognosis for, 80
- villous cistern formation, 19. *See also*  
 early pregnancy loss
- villous dysmaturity, 83–85. *See also*  
 delayed villous maturation
- villous edema  
 chronic, 109–11  
 diffuse, 111–12  
 clinical context, 111  
 CNS injury and, 324  
 features, 111, 112  
 pathogenesis for, 111  
 prognosis for, 112  
 patchy, 112  
   features, 112  
   prognosis for, 112
- villous hydrops, 109–11. *See also*  
 hydrops placentalis
- villous infarcts  
 centrally hemorrhagic, 66–67  
 intervillous thrombus with, 66–67  
 remote and recent, 65–66  
 clinical context, 65  
 features of, 65–66  
 multiple, 65  
 pathogenesis for, 65  
 prognosis for, 66
- villous mesenchyme, 24
- villous paucity, 62–65. *See also*  
 accelerated villous maturation
- villous stromal cells, 18. *See also* early  
 pregnancy loss
- villous stromal hemorrhage,  
 107–8. *See also* intravillous  
 hemorrhage
- villous stromal-vascular karyorrhexis,  
 93, 100. *See also* fetal vascular  
 malperfusion
- villous trophoblast basement  
 membrane, mineralization of,  
 238–39. *See also* Bartter  
 syndrome
- villous trophoblastic lineage, 21–34.  
*See also* choriocarcinoma;  
 complete hydatidiform mole  
 diandric uniparental disomy of  
 chromosome 11, 25  
 hydropic phenotype, 26–27  
 invasive hydatidiform mole,  
 30–31  
   ancillary diagnosis of, 30  
   clinical context for, 30  
   differential diagnosis of, 30  
   features of, 30  
   prognosis of, 30–31  
 partial hydatidiform mole, 21–24  
   ancillary diagnosis for, 23–24  
   clinical context for, 21  
   differential diagnosis for, 22–23  
   features of, 21–22, 23  
   pathogenesis of, 21  
   prognosis for, 24  
   triploidy and, 21  
 vitelline hemangioma, 173–76  
 VUE. *See* villitis of unknown etiology
- Wharton's jelly, 167–68, 171, 203
- yolk sac tumor, 233  
 clinical context, 233  
 features, 233  
 pathogenesis for, 233
- zygosity. *See* dichorionic twins;  
 monochorionic diamniotic  
 twins